This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter amid inventory decreases in the U.S.
The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.
While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.
Are you currently in sales, or involved in a business that depends on strong sales results? What about the extremely competitive world of medical device sales? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC., Toastmasters Champion.
Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.
Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.
Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.
But sales could climb even higher if it works as a preventive treatment too. Executives based their projections on contracts already in place for the drug, known as molnupiravir.
The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.
Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.
A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.
billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks. The pharmaceutical company expects $2.5
The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.
The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines.
Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.
The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.
Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter. in the same quarter last year.
Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage.
The drugmaker again increased its forecast for 2021 sales, this time to $36 billion, or about 80% of what the rest of Pfizer's business is expected to earn this year.
Company executives claimed “unprecedented demand” for the Duchenne gene therapy will soon cause a sales surge, countering a dip in quarterly sales and financial projections that raised concerns among investors.
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ambitious sales target and Syndax inked a lucrative royalty deal.
The biotech recently stopped a trial of its experimental conditioning regimen over safety concerns. Now it’s halting further development work as it undertakes a strategic review.
Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and Johnson & Johnson.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content